As­traZeneca ends dai­ly GLP-1/glucagon tri­als in switch to week­ly in­jec­tion op­tion for NASH, oth­er in­di­ca­tions

As­traZeneca is end­ing clin­i­cal tri­als of a dai­ly GLP-1/glucagon co-ag­o­nist as the Big Phar­ma re­fo­cus­es its re­sources on a week­ly in­jec­tion that goes af­ter the pop­u­lar di­a­betes and obe­si­ty tar­get, which is in the spot­light thanks to No­vo Nordisk, Eli Lil­ly and oth­er drug­mak­ers.

The Big Phar­ma had been test­ing its dai­ly op­tion, the large mol­e­cule co­tadu­tide, in a Phase IIb/III in pa­tients with the fat­ty liv­er dis­ease non-al­co­holic steato­hep­ati­tis (NASH), as well as ear­ly-stage stud­ies for he­pat­ic im­pair­ment and car­diac re­po­lar­iza­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER